Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma : Episode 4

Opinion

Video

January 2, 2024

CAR T-cells as Third-line and Beyond Therapy for FL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

EP: 1.Current Treatment Options in First-line FL

EP: 2.ASH 2023 Updates on Frontline Therapies in FL

EP: 3.Current Treatment Options in Second-line FL

EP: 4.CAR T-cells as Third-line and Beyond Therapy for FL

EP: 5.Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

EP: 6.Tazemetostat as Third-line and Beyond Therapy for FL

EP: 7.Zanubrutinib as Third-Line and Beyond Therapy for FL

EP: 8.Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

EP: 9.Choosing CAR T-cells as Third-line and Beyond Therapy for FL

EP: 10.Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

EP: 11.Unmet Needs in Treating Relapsed/Refractory FL

EP: 12.Current Treatment Options in First-Line MCL

EP: 13.ASH 2023 Updates on Frontline Therapies in MCL

EP: 14.Current Treatment Options in Second-line MCL

EP: 15.Current Treatment Options in Third-line MCL

EP: 16.Sequencing Therapies in the Third-Line and Beyond Setting for MCL

EP: 17.Future Directions and Unmet Needs in Relapsed/Refractory MCL

Related Videos

Tiago Biachi, MD, PhD

5 KOLs are featured in this series.

5 KOLs are featured in this series.

5 KOLs are featured in this series.

Daniel DeAngelo, MD, PhD

5 KOLs are featured in this series.

Related Content

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com

November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

OncLive's Top 5 Stories of the Week in Oncology

November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

Narjust Florez, MD

September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com

November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

Leukemia

November 6th 2024

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

Related Content

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com

November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

OncLive's Top 5 Stories of the Week in Oncology

November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

Narjust Florez, MD

September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com

November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

Leukemia

November 6th 2024

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

Latest Conference Coverage

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors

Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.